SCHEMBL2844736

SCHEMBL2844736

NC1C2CCC1CN(Cc1ccccc1)C2

nearest known ligand 0.69

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
FUCA1 P04066 2/20 0.53
SIGMAR1 Q99720 1/20 0.50
DRD2 P14416 1/20 0.49
DRD3 P35462 1/20 0.49
ACHE P22303 3/20 0.49
BCHE P06276 2/20 0.49
BACE1 P56817 2/20 0.49
GRIN2B Q13224 1/20 0.48
HRH3 Q9Y5N1 1/20 0.48
CYP1A2 P05177 1/20 0.47
CYP3A4 P08684 1/20 0.47
CYP2D6 P10635 1/20 0.47
CYP2C19 P33261 1/20 0.47
ALDH1A1 P00352 1/20 0.47
CCR3 P51677 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21777836 1.00 FUCA1 (0.53) FUCA1SIGMAR1DRD2DRD3ACHE
SCHEMBL2844733 1.00 FUCA1 (0.53) FUCA1SIGMAR1DRD2DRD3ACHE
SCHEMBL21777835 1.00 FUCA1 (0.53) FUCA1SIGMAR1DRD2DRD3ACHE
SCHEMBL21773216 1.00 FUCA1 (0.53) FUCA1SIGMAR1DRD2DRD3ACHE
SCHEMBL21777837 1.00 FUCA1 (0.53) FUCA1SIGMAR1DRD2DRD3ACHE
SCHEMBL21777260 1.00 FUCA1 (0.53) FUCA1SIGMAR1DRD2DRD3ACHE
SCHEMBL21773211 1.00 FUCA1 (0.53) FUCA1SIGMAR1DRD2DRD3ACHE
SCHEMBL6616536 0.93 FUCA1 (0.50) FUCA1SIGMAR1DRD2DRD3ACHE
SCHEMBL5071734 0.90 ACHE (0.55) SIGMAR1DRD2DRD3ACHEBCHE
SCHEMBL4090277 0.89 KDM1A (0.54) FUCA1SIGMAR1DRD2DRD3ACHE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-113165992-B Process for preparing tert-butyl exo-N- (3-azabicyclo [3.2.1] oct-8-yl) carbamate 豪夫迈·罗氏有限公司 2024-08-06 CN claimed
CN-113165992-A Method for producing exo-N- (3-azabicyclo [3.2.1] octan-8-yl) carbamic acid tert-butyl ester 豪夫迈·罗氏有限公司 2021-07-23 CN claimed
US-6559162-B2 Electrophysiological activity ASTRAZENECA AB (SE) 2003-05-06 US claimed
US-12275709-B2 Process for the preparation of exo-tert-butyl N-(3-azabicyclo[3.2.1]octan-8-yl)carbamate HOFFMANN-LA ROCHE INC. (US) 2025-04-15 US disclosed
CN-113165992-B Process for preparing tert-butyl exo-N- (3-azabicyclo [3.2.1] oct-8-yl) carbamate 豪夫迈·罗氏有限公司 2024-08-06 CN disclosed
EP-3902779-B1 PROCESS FOR THE PREPARATION EXO-TERT-BUTYL N-(3-AZABICYCLO[3.2.1]OCTAN-8-YL)CARBAMATE HOFFMANN LA ROCHE (CH) 2023-01-18 EP disclosed
EP-3902779-B1 PROCESS FOR THE PREPARATION EXO-TERT-BUTYL N-(3-AZABICYCLO[3.2.1]OCTAN-8-YL)CARBAMATE HOFFMANN LA ROCHE (CH) 2023-01-18 EP disclosed
US-20220073469-A1 PROCESS FOR THE PREPARATION OF EXO-TERT-BUTYL N-(3-AZABICYCLO[3.2.1]OCTAN-8-YL)CARBAMATE HOFFMANN-LA ROCHE INC. (US) 2022-03-10 US disclosed
EP-3902779-A1 PROCESS FOR THE PREPARATION EXO-TERT-BUTYL N-(3-AZABICYCLO[3.2.1]OCTAN-8-YL)CARBAMATE F. Hoffmann-La Roche AG (CH) 2021-11-03 EP disclosed
WO-2020136188-A1 PROCESS FOR THE PREPARATION EXO-TERT-BUTYL N-(3-AZABICYCLO[3.2.1]OCTAN-8-YL)CARBAMATE F. HOFFMANN-LA ROCHE AG (CH) 2020-07-02 WO disclosed
WO-2020136188-A1 PROCESS FOR THE PREPARATION EXO-TERT-BUTYL N-(3-AZABICYCLO[3.2.1]OCTAN-8-YL)CARBAMATE F. HOFFMANN-LA ROCHE AG (CH) 2020-07-02 WO disclosed
WO-2007039884-A1 3 -AZABICYCLOOCTANE DERIVATIVES AS MUSCARINIC RECEPTOR ANTAGONISTS RANBAXY LABORATORIES LIMITED (IN) 2007-04-12 WO disclosed
WO-2007007281-A2 MUSCARINIC RECEPTOR ANTAGONISTS RANBAXY LABORATORIES LIMITED (IN) 2007-01-18 WO disclosed
US-20060276487-A1 New compounds useful for DPP-IV enzyme inhibition SANOFI-AVENTIS (FR) 2006-12-07 US disclosed
EP-1664031-A2 ADAMANTANE AND AZABICYCLO-OCTANE AND NONANE DERIVATIVES PROCESS OF THEIR PREPARATION AND THEIR USE AS DPP-IV INHIBITORS Sanofi-Aventis (FR) 2006-06-07 EP disclosed
WO-2006056863-A1 PYRIDO’2, 3-D!PYRIMIDINES AS ANTI-INFLAMMATORY AGENTS RANBAXY LABORATORIES LIMITED (IN) 2006-06-01 WO disclosed
WO-2005021536-A2 ADAMANTANE AND AZABICYCLO-OCTANE AND NONANE DERIVATIVES, PROCESS OF THEIR PREPARATION AND THEIR USE AS DPP-IV INHIBITORS SANOFI-AVENTIS (FR) 2005-03-10 WO disclosed
WO-2005021536-A2 ADAMANTANE AND AZABICYCLO-OCTANE AND NONANE DERIVATIVES, PROCESS OF THEIR PREPARATION AND THEIR USE AS DPP-IV INHIBITORS SANOFI-AVENTIS (FR) 2005-03-10 WO disclosed
US-4719217-A Certain N-azabicycloalkyl-benzamides useful in the treatment of impaired gastro-intestinal motility or emesis BEECHAM GROUP P.L.C. (GB) 1988-01-12 US disclosed
EP-0212802-A1 Substituted benzamides BEECHAM GROUP PLC (GB) 1987-03-04 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12275709-B2 Process for the preparation of exo-tert-butyl N-(3-azabicyclo[3.2.1]octan-8-yl)carbamate HUWE1, APP, PSEN1 FUCA1 2866/4885SIGMAR1 4618/4885DRD2 1515/4885
US-20220073469-A1 PROCESS FOR THE PREPARATION OF EXO-TERT-BUTYL N-(3-AZABICYCLO[3.2.1]OCTAN-8-YL)CARBAMATE HUWE1, APP, PSEN1 FUCA1 2866/4885SIGMAR1 4618/4885DRD2 1515/4885
US-20060276487-A1 New compounds useful for DPP-IV enzyme inhibition DPP4, DPP7, DPP9 FUCA1 845/4885SIGMAR1 3847/4885DRD2 2579/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.